Vecuronium-associated axonal motor neuropathy: A variant of critical illness polyneuropathy?

Thomas J. Geller, Kitti Kaiboriboon, Glen A. Fenton, Ghazala R. Hayat

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Neuromuscular blocking agents are routinely used as an adjunct therapy for critically ill patients. Unlike many neuromuscular blocking agents, vecuronium does not cause significant histamine release, which may lead to bronchoconstriction. Due to a short duration of action and limited accumulation, vecuronium has been widely used. Prolonged ventilatory dependence due to persistent neuromuscular blockade has been reported in patients treated with vecuronium. We report a case of an 8-year-old girl who had a primarily motor axonopathy presenting with weakness after extended vecuronium administration with prolonged course of recovery. This primarily motor neuropathy with axonal features may be a variant of critical illness polyneuropathy, a rarely reported condition in pediatric patients.

Original languageEnglish (US)
Pages (from-to)579-582
Number of pages4
JournalNeuromuscular Disorders
Issue number6-7
StatePublished - 2001
Externally publishedYes


  • Critical illness polyneuropathy
  • Neuromuscular blockade
  • Non-depolarizing neuromuscular blocking agent
  • Polyneuropathy
  • Vecuronium

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Clinical Neurology
  • Genetics(clinical)


Dive into the research topics of 'Vecuronium-associated axonal motor neuropathy: A variant of critical illness polyneuropathy?'. Together they form a unique fingerprint.

Cite this